{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:51:39Z","timestamp":1787741499821,"version":"build-2784847793"},"reference-count":46,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T00:00:00Z","timestamp":1429920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD\u2010MCI. Patients with PD\u2010MCI (n\u2009=\u200928) were enrolled in a 24\u2010week, randomized, double\u2010blind, placebo\u2010controlled, crossover, single\u2010site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer's Disease Cooperative Study\u2014Clinical Global Impression of Change (ADCS\u2010CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale\u20102 (DRS\u20102), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson's Disease Questionnaire (PDQ\u20108). Twenty\u2010six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed\u2010effects model\u2009=\u20090.44, <jats:italic>F<\/jats:italic>[<jats:italic>df<\/jats:italic>]\u2009=\u20093.01 [1, 24], <jats:italic>P<\/jats:italic>\u2009=\u20090.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient\u2009=\u2009\u20132.41, <jats:italic>F<\/jats:italic>[<jats:italic>df<\/jats:italic>]\u2009=\u20095.81 [1, 22.05], <jats:italic>P<\/jats:italic>\u2009=\u20090.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ\u20108 (regression coefficient\u2009=\u20094.55, <jats:italic>F<\/jats:italic>[<jats:italic>df<\/jats:italic>]\u2009=\u20093.93 [1, 14. 79], <jats:italic>P<\/jats:italic>\u2009=\u20090.09) and the State Anxiety Inventory (regression coefficient\u2009=\u2009\u20131.24, <jats:italic>F<\/jats:italic>[<jats:italic>df<\/jats:italic>]\u2009=\u20093.17 [1, 33], <jats:italic>P<\/jats:italic>\u2009=\u20090.08). Rivastigmine in PD\u2010MCI showed a trend effect for improvements on a global rating of cognition, disease\u2010related health status, and anxiety severity, and significant improvement on a performance\u2010based measure of cognitive abilities. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.26236","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T10:58:53Z","timestamp":1429959533000},"page":"912-918","source":"Crossref","is-referenced-by-count":110,"title":["Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo\u2010controlled study"],"prefix":"10.1002","volume":"30","author":[{"given":"Eugenia","family":"Mamikonyan","sequence":"first","affiliation":[{"name":"Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania  Philadelphia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon X.","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology Perelman School of Medicine at the University of Pennsylvania  Philadelphia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Melvin","sequence":"additional","affiliation":[{"name":"Duke University Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania  Philadelphia USA"},{"name":"Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.3.387"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24893"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f39d0e"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52219.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.06.011"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23073"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21853"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21686"},{"key":"e_1_2_7_11_1","unstructured":"Alzheimer's Association. Changing the trajectory of Alzeheimer's disease: a national imperative. [cited 2010 June 9]. Available from:http:\/\/www.alz.org\/alzheimers_disease_trajectory.asp."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1745"},{"key":"e_1_2_7_14_1","first-page":"595","article-title":"The clinical features of Parkinson's disease in 100 histologically proven cases","volume":"60","author":"Hughes AJ","year":"1993","journal-title":"Adv Neurol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fc29c9"},{"key":"e_1_2_7_16_1","volume-title":"Dementia Rating Scale\u20142","author":"Mattis S","year":"2001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01380.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acq030"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21507"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187889.17253.b1"},{"issue":"1","key":"e_1_2_7_22_1","first-page":"308","article-title":"Psychometric properties of the brief Penn Daily Activities Questionnaire (PDAQ) for Parkinson's disease","volume":"28","author":"Weintraub D","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_2_7_23_1","first-page":"S22","article-title":"Validity and reliability of the Alzheimer's Disease co\u2010operative study: clinical global impression of change","volume":"11","author":"Schneider L","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-3-4"},{"key":"e_1_2_7_25_1","volume-title":"Gordon Diagnostic System","author":"Gordon M","year":"1986"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1037\/0882-7974.14.4.627"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1330"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.06.006"},{"key":"e_1_2_7_29_1","first-page":"165","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention","author":"Sheikh JI","year":"1986"},{"key":"e_1_2_7_30_1","first-page":"280","article-title":"Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease","volume":"21","author":"Friedberg G","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.4.2.134"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.6.708"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70146-2"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.050682"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529876"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxp046"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0175-2"},{"key":"e_1_2_7_39_1","first-page":"1654","article-title":"Benefits of rivastigmine on attention in dementia associated with Parkinson disease","volume":"65","author":"Wesnes KA","year":"2006","journal-title":"J Neural Transm"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317510367486"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21077"},{"key":"e_1_2_7_42_1","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","volume":"3","author":"Rolinski M","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70212-X"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2010.11.015"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25575"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0891988712445086"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00007"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26236","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:48:38Z","timestamp":1760960918000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,25]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/mds.26236"],"URL":"https:\/\/doi.org\/10.1002\/mds.26236","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,25]]}}}